DLCS for Predicting Neoadjuvant Chemotherapy Response
Sponsor
Zhejiang Cancer Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05617469
Collaborator
(none)
1,100
1
13
84.8
Study Details
Study Description
Brief Summary
The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
1100 participants
Observational Model:
Other
Time Perspective:
Retrospective
Official Title:
Deep Learning Radio-clinical Signatures for Predicting Neoadjuvant Chemotherapy Response and Prognosis From Pretreatment CT Images of LAGC Patients
Actual Study Start Date
:
Jul 1, 2022
Anticipated Primary Completion Date
:
Jan 30, 2023
Anticipated Study Completion Date
:
Jul 31, 2023
Outcome Measures
Primary Outcome Measures
- Tumor regression grade [3 months]
Tumor regression grade
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- patients with GC/EGJC confirmed by pathological examination; 2) patients who underwent D2 lymphadenectomy; 3) patients who received at least two cycles of preoperative chemotherapy; 4) patients with negative resection margins; and 5) patients with complete CT image data and clinical data.
Exclusion Criteria:
- patients unable to undergo D2 radical gastrectomy after neoadjuvant therapy; and 2) patients with incomplete CT images and clinical data.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) | Hangzhou | Zhejiang | China | 310022 |
Sponsors and Collaborators
- Zhejiang Cancer Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Xiangdong Cheng,
Professor,
Zhejiang Cancer Hospital
ClinicalTrials.gov Identifier:
NCT05617469
Other Study ID Numbers:
- AICT-01
First Posted:
Nov 15, 2022
Last Update Posted:
Nov 15, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: